Latest NewsOct 30, 2025HiFiBiO Therapeutics Announces the Appointment of Leading I&I Experts to its Scientific Advisory BoardAll Filter By: Year20252024202320222021202020192018201720162015Oct 23, 2023Drug Intelligence Science (DIS®) – A Cutting-Edge Translational Platform Pioneered by HiFiBiO Therapeutics – Featured in Drug Discovery TodayOct 9, 2023HiFiBiO Therapeutics Receives Approval from Chinese NMPA for IND Application for HFB200301, an Innovative Anti-Tumor Monoclonal AntibodyAug 28, 2023Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023Jun 28, 2023Robert Andtbacka, MD, CM joins HiFiBiO Therapeutics as Chief Medical OfficerJun 23, 2023HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors< 1 2 3 4 5 6 … 18 >
